

---

# TABLE OF CONTENTS

<b>PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE AND PUBLIC HEALTH</b> . . . . .	<b>1</b>
<i>Atherosclerotic Cardiovascular Disease Risk Factors, Risk Assessment Tool and Calculators, Dietary and Lifestyle Modifications, Tobacco Cessation Therapies, Weight Management Therapies, Diabetes Management, Aspirin Usage, Complementary and Alternative Medicine Therapies.</i>	
<b>DYSLIPIDEMIA</b> . . . . .	<b>55</b>
<i>Role of Lipoproteins in Development of ASCVD, Risk Assessment for Primary Prevention, Review of Current Practice Guidelines, Statin Therapy, Non-Statins Therapies; Strategies in Specific Patient Populations.</i>	
<b>BLOOD PRESSURE MANAGEMENT IN ADULT PATIENTS</b> . . . . .	<b>91</b>
<i>Classification, Diagnosis, Screening and Management of Risk Factors, Secondary Causes, Blood Pressure Measurement Methods, Setting Blood Pressure Goals, Non-pharmacologic and Pharmacologic Therapy, Treatment in Special Populations, Resistant Hypertension, Hypotension.</i>	
<b>STABLE ATHEROSCLEROTIC DISEASE</b> . . . . .	<b>139</b>
<i>Stable Ischemic Heart Disease: Pathophysiology, Clinical Presentation, Classification, Diagnostic Procedures, Goals of Treatment, Pharmacologic Therapies (antiplatelet, antianginal), Nonpharmacologic Therapies (PCI, CABG); Secondary Prevention of Atherosclerotic Stroke or Transient Ischemic Attack, Peripheral Arterial Disease Screening and Treatment.</i>	
<b>ANTICOAGULATION</b> . . . . .	<b>181</b>
<i>Stroke Prevention in Nonvalvular Atrial Fibrillation, Risk Stratification Scores, Warfarin and Direct Oral Anticoagulant Therapies, Selecting Anticoagulant Therapies in Specific Patient Populations, Antiplatelet Therapies, Prevention and Treatment of Venous Thromboembolism, Reversal of Anticoagulation.</i>	
<b>ARRHYTHMIAS</b> . . . . .	<b>237</b>
<i>Electrocardiogram Interpretation, Sinus Bradycardia, Atrioventricular Block, Atrial Fibrillation (Rate and Rhythm Control Strategies, Conversion Therapies; Treatment Strategies in Special Populations), Supraventricular Tachycardia, Premature Ventricular Complexes, Ventricular Tachycardia.</i>	
<b>DRUG-INDUCED CARDIOVASCULAR DISEASE AND DRUGS TO AVOID IN CARDIOVASCULAR DISEASE</b> . . . . .	<b>317</b>
<i>Drug-Induced: Supraventricular and Ventricular Arrhythmias, Valvular Disease, Hyper- and Hypotension, Heart Failure, and Myocardial Ischemia; Medications Associated with Increased Cardiovascular Risk; Drugs to Avoid in Specific Populations.</i>	
<b>CHRONIC HEART FAILURE</b> . . . . .	<b>357</b>
<i>Classification, Staging, Diagnosis, Role of Biomarkers, Pathophysiology, Pharmacotherapy of Heart Failure with Reduced Ejection Fraction, Device and Sensor Therapy, Pharmacotherapy of Heart Failure with Preserved Ejection Fraction; Important Comorbidities in Heart Failure, Nonpharmacologic Considerations.</i>	

---

<b>ACUTE DECOMPENSATED HEART FAILURE. . . . .</b>	<b>429</b>
<i>Pathophysiology, Clinical Presentation, Hemodynamic Parameters, Role of Biomarkers, Hemodynamic Subsets and Therapy, Diuretic Dosing Strategies, Inotropic Therapies, Vasodilator Therapies.</i>	
<b>HEART TRANSPLANT AND MECHANICAL CIRCULATORY SUPPORT . . . . .</b>	<b>457</b>
<i>Criteria for Advanced Heart Failure, Candidacy for Advanced Therapies (Heart Transplant and Durable Left Ventricular Assist Devices [LVAD]), Heart Transplantation (Pre-transplant, Perioperative, and Post-transplant Management), Percutaneous Ventricular Assist Devices, Extracorporeal Membrane Oxygenation, Durable Continuous-Flow LVADs.</i>	
<b>ACUTE CORONARY SYNDROME . . . . .</b>	<b>503</b>
<i>Subclassifications and Clinical Findings, Selection of Initial Treatment Strategy (Invasive vs. Conservative), Anti-Ischemic Interventions, Antiplatelet, Anticoagulant and Antithrombotic Strategies, Post-Percutaneous Intervention Complications, Lipid-Lowering Strategies, Coronary Artery Bypass Grafting Revascularization, Special Populations, Secondary Prevention and Discharge Medication Reconciliation, Quality Metrics.</i>	
<b>CARDIOVASCULAR EMERGENCIES. . . . .</b>	<b>553</b>
<i>Advance Cardiac Life Support Protocols, Targeted Temperature Management, Cardiac Tamponade, Shock Syndromes, Hypertensive Crisis, Acute Aortic Syndrome, and Acute Ischemic Stroke.</i>	
<b>PULMONARY ARTERIAL HYPERTENSION . . . . .</b>	<b>609</b>
<i>Classification, Risk Factors, Pathophysiology, Clinical Presentation, Diagnosis, Risk Assessment, Treatment Goals, Pharmacologic Therapy Options, Selecting Therapy in Specific Patient Populations.</i>	
<b>SPECIALIZED TOPICS IN CARDIOVASCULAR DISEASE . . . . .</b>	<b>641</b>
<i>Infective Endocarditis (Prevention, Common Pathogens, Treatment, Role of Antithrombotic Therapy); Pericarditis (Diagnosis, Classification, Treatment, Special Pericardial Syndromes); Myocarditis (Diagnosis, Clinical Presentation and Management); Valvular Disorders (Atrial and Ventricular Disorders, Diagnosis, Presentation, Secondary Prevention of Rheumatic Heart Disease in Adults, Symptom-based Guideline Directed Pharmacologic Therapy, Valve Replacement including TAVR, and Antithrombotic Therapy).</i>	
<b>TRANSLATION OF EVIDENCE INTO PRACTICE . . . . .</b>	<b>681</b>
<i>Cardiovascular Literature Sources, Biostatistical Methods Used in Cardiovascular Trials, Choosing the Most Appropriate Statistical Test, Interpreting Statistical Data, Correlation, Regression and Survival Analysis, Research Design and Methodology, Determining Internal and External Validity, Cardiovascular Study Endpoints.</i>	
<b>PRINCIPLES OF CARDIOLOGY PHARMACY PRACTICE ADMINISTRATION. . . . .</b>	<b>713</b>
<i>Policy and Guideline Development, Formulary Development and Management, Quality and Performance Improvement, Documentation Processes for Clinical Pharmacy Services, Pharmacoeconomics, Legal Compliance, Pharmacist Scope of Practice, Credentialing and Privileging, Safe Medication Use, Adverse Drug Reaction Reporting.</i>	

---

## ADDITIONAL RESOURCES

### **PHARMACOGENOMICS OF CARDIOVASCULAR DISEASE .....757**

*Precision vs. Personalized Medicine; Pharmacogenetic Testing Methods, Types of Genetic Polymorphisms, Drug Labeling and Pharmacogenetics, Role of the Clinical Pharmacogenomics Implementation Consortium (CPIC), CPIC Guidelines for Clopidogrel, Simvastatin, and Warfarin, Dosing Strategies in Specific Populations.*